Impact of Renal Function on Ticagrelor-Induced Antiplatelet Effects in Coronary Artery Disease Patients
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Dual antiplatelet therapy consisting in aspirin and clopidogrel is the cornerstone of the
treatment of the prevention of the thrombotic events in patients with coronary artery disease
(CAD), showing a reduction in adverse events.
Details
Lead Sponsor:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia